» Articles » PMID: 36355881

Clinical Features Related to Severity and Mortality Among COVID-19 Patients in a Pre-Vaccine Period in Luanda, Angola

Abstract

Background: Infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with clinical features of diverse severity. Few studies investigated the severity and mortality predictors of coronavirus disease 2019 (COVID-19) in Africa. Herein, we investigated the clinical features of severity and mortality among COVID-19 patients in Luanda, Angola. Methods: This multicenter cohort study involved 101 COVID-19 patients, between December 2020 and April 2021, with clinical and laboratory data collected. Analysis was done using independent-sample t-tests and Chi-square tests. The results were deemed significant when p < 0.05. Results: The mean age of patients was 51 years (ranging from 18 to 80 years) and 60.4% were male. Fever (46%), cough (47%), gastrointestinal symptoms (26.7%), and asthenia (26.7%), were the most common symptoms. About 64.4% of the patients presented coexistent disorders, including hypertension (42%), diabetes (17%), and chronic renal diseases (6%). About 23% were non-severe, 77% were severe, and 10% died during hospitalization. Variations in the concentration of neutrophil, urea, creatinine, c-reactive protein, sodium, creatine kinase, and chloride were independently associated with severity and/or mortality (p < 0.05). Conclusion: Several factors contributed to the severity and mortality among COVID-19 patients in Angola. Further studies related to clinical features should be carried out to help clinical decision-making and follow-up of COVID-19 patients in Angola.

Citing Articles

Clinical characteristics and variables associated with COVID-19 morbidity and mortality in Luanda, Angola, in the first year of the pandemic.

Arrais M, Dias W, Silva M, Neto L, Pedro N, Jungo S Afr Health Sci. 2024; 23(4):51-63.

PMID: 38974263 PMC: 11225435. DOI: 10.4314/ahs.v23i4.9.


Insights into SARS-CoV-2 in Angola during the COVID-19 peak: Molecular epidemiology and genome surveillance.

Francisco N, van Wyk S, Moir M, San J, Sebastiao C, Tegally H Influenza Other Respir Viruses. 2023; 17(9):e13198.

PMID: 37744993 PMC: 10515134. DOI: 10.1111/irv.13198.


COVID-19: Current Status and Future Prospects.

Leggat P, Frean J, Blumberg L Trop Med Infect Dis. 2023; 8(2).

PMID: 36828510 PMC: 9966066. DOI: 10.3390/tropicalmed8020094.

References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
Sohrabi C, Alsafi Z, ONeill N, Khan M, Kerwan A, Al-Jabir A . World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020; 76:71-76. PMC: 7105032. DOI: 10.1016/j.ijsu.2020.02.034. View

5.
Li T, Lu H, Zhang W . Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):687-690. PMC: 7103696. DOI: 10.1080/22221751.2020.1741327. View